HCW Biologics (HCWB) Stock: Big Revenue Quarter Can’t Mask Nasdaq Delisting Threat

TLDR

• HCW Biologics posted Q1 2026 revenue of $6.54M, up from just $5,065 in the prior-year period, driven by a $6.5M license deal with Beijing Trimmune.
• The company swung to a net income of $3.47M in Q1 2026 versus a loss of $2.2M a year earlier.
• Its Phase 1 trial of HCW9302 for alopecia areata is on schedule, with preliminary data from two dose levels expected in H1 2026.
• HCW Biologics faces a Nasdaq delisting threat over its failure to meet the $1.00 minimum bid price requirement, with a hearing granted on May 5, 2026.
• The company still carries going concern risk and is pursuing additional financing and business development activities.

HCW Biologics (HCWB) turned in a strong revenue quarter, but the headline numbers come with some serious asterisks.

The Florida-based clinical-stage biopharmaceutical company reported Q1 2026 revenue of $6.54 million, a dramatic jump from just $5,065 in the same period last year. HCWB stock was down 3.55% following the release. The surge was almost entirely tied to a single licensing deal — a $6.5 million license fee from Beijing Trimmune Biotech, which closed on March 16, 2026.

HCW Biologics Inc., HCWB

The deal gave Trimmune exclusive worldwide rights to HCW11-006. In return, HCW Biologics received $3.5 million in cash upfront, net of taxes $2.9 million, plus a transferable minority equity stake in Trimmune valued at another $3.5 million.

Net income for the quarter came in at $3.47 million, compared to a loss of $2.2 million in Q1 2025. Operating income was $3.24 million. Basic and diluted earnings per share came in at $0.37, based on weighted average shares outstanding of around 5.43 million.

On the cost side, the company trimmed both R&D and general and administrative expenses. R&D spend fell 15% to $1.3 million, while G&A dropped 18% to $1.8 million compared to a year earlier.

Pipeline Update

The company’s lead clinical asset, HCW9302, is moving through a Phase 1 trial for alopecia areata. Two clinical sites are actively enrolling patients, and no dose-limiting toxicities have been reported so far.

Preliminary data from the first two dose levels is expected in the first half of 2026, with a full Phase 1 readout due in Q4 2026. HCW9302 is a first-in-kind IL-2 fusion protein designed to expand regulatory T cells and suppress the autoimmune activity that attacks hair follicles.

Separately, a March 2026 publication in Science Advances showed that HCW9206, a commercial-ready compound, could improve CAR-T cell manufacturing and potentially boost clinical efficacy against cancer and HIV. The company is actively shopping for a corporate partner to commercialize that program.

Nasdaq Delisting Risk

The financials come with a significant cloud overhead: HCW Biologics is fighting to stay listed on Nasdaq.

On May 5, 2026, the company was granted a hearing to appeal a Nasdaq delisting determination tied to its failure to maintain a minimum bid price of $1.00 per share. The outcome of that hearing is pending.

The company has also disclosed going concern risk, noting as of March 31, 2026, that substantial doubt exists about its ability to continue operations for the next 12 months without additional funding. A $1.5 million equity financing completed in February 2026 offered some relief, but management acknowledges the path forward depends on business development and additional capital.

The Nasdaq hearing outcome remains pending as of the report date.

The post HCW Biologics (HCWB) Stock: Big Revenue Quarter Can’t Mask Nasdaq Delisting Threat appeared first on CoinCentral.